The aim of this study is to evaluate the efficiency of proton pump inhibitors in the treatment of gastric and duodenal ulcers as based on literature. Materials and methods: The materials of this research are the results of 86 original studies on the effectiveness of proton pump inhibitors analysis. Descriptive, statistical, retrospective. According to the clinical random researches, Omeprazole preparations are not included in the list due to proven better effectiveness of Esomeprazole drugs. Moreover, lansoprazole drugs are not included according to proven short-acid inhibitory effect. In addition, the brand of mentioned above preparation does not exist on the pharmaceutical market of Ukraine. Furthermore, rabeprazole preparations are presented in the research by Pariet (brand) and by the effective generic Barol, while pantoprazole preparations are represented in the research by Kontrolok (brand) and by the generic Pultset, as well as by Nolpaza. Herein, the Pantosan effect was not significantly different from the effect of Pultset and Nolpaza, but the preparation is much more expensive. In terms of efficiency (%), 4 week repair of mucosal defects was carried out by way of the following treatment regimens: Barol+ Amoxicillin+ Clarythromycin (90.9±6.2), Pariet+ Amoxicillin+ Clarythromycin (83±2.6), Kontrolok+ Amoxicillin+ Clarythromycin (100±1.3), Pultset+ Amoxicillin+ Clarythromycin (88±4.1), Nolpaza+ Amoxicillin+ Clarythromycin (72±4.1), Ezolonh+ Amoxicillin+ Clarythromycin (87.7±3.8), Neksium+ Amoxicillin+ Clarythromycin (96.1±3.1).